Panitumumab labeled with Auger electron-emitting 197gHg/197mHg: cytotoxicity on human breast cancer cells and tumour and normal tissue uptake in mice with EGFR-overexpressing breast cancer xenografts
Arthur C K Chu, Felix Ho, Conrad Chan, Zhongli Cai, Yumeela Ganga-Sah, Parmissa Randhawa, Caterina F Ramogida, Valery Radchenko, Raymond M Reilly · 2026
Read Panitumumab labeled with Auger electron-emitting 197gHg/197mHg: cytotoxicity on human breast cancer cells and tumour and normal tissue uptake in mice with EGFR-overexpressing breast cancer xenografts by Arthur C K Chu, Felix Ho, Conrad Chan, Zhongli Cai, Yumeela Ganga-Sah, Parmissa Randhawa, Caterina F Ramogida, Valery Radchenko, Raymond M Reilly (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13269620.txt.
Description
Arthur C K Chu and co-authors published a journal article in 2026 on a radioactive form of an antibody drug for breast cancer. The antibody targets a growth receptor found in large amounts on some cancer cells. Two mercury forms attached to it emit short-range electrons that damage DNA up close.
The labeled drug bound strongly, at 87 to 91 percent, to receptor-rich cancer cells and moved into their nuclei. Nuclear dose rose with the number of receptors on each cell line. Survival of the richest cell line fell below 5 percent, while the unlabeled drug did not cut survival. Blocking the receptor restored survival to about 60 percent. Tumors in mice took up the drug on scans.
Catalog record
| CREATOR | Arthur C K Chu, Felix Ho, Conrad Chan, Zhongli Cai, Yumeela Ganga-Sah, Parmissa Randhawa, Caterina F Ramogida, Valery Radchenko, Raymond M Reilly |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59139 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |